Patents Assigned to Hadasit
  • miR-122* as an active micro-RNA, compositions comprising the same and uses thereof
    Patent number: 10392617
    Abstract: The present invention provides miR-122* as a functional microRNA molecule, compositions comprising the same and uses thereof for treatment of various conditions, such as, cancer. Further provided are methods for increasing the expression, stability and/or activity of p53 in a target cell or method for inducing cancer cell death, the methods comprising introducing into the cell a miR-122* polynucleotide molecule or a vector expressing or encoding the same.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: August 27, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Hilla Giladi, Alina Simerzin, Yael Hantz, Sagit Arbel Alon, Eithan Galun
  • COMBINATIONS OF BETA-GLYCOLIPIDES AND 4-[(2-AMINO-3,5-DIBROMOPHENYL)METHYLAMINO]CYCLOHEXAN-1-OL, COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING AND PROTEIN AGGREGATIONS
    Publication number: 20190254992
    Abstract: Provided are therapeutic combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, as well as compositions, kits and methods using the same in treating disorders associated with protein misfolding and for immunomodulation.
    Type: Application
    Filed: June 29, 2017
    Publication date: August 22, 2019
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, SHAARE ZEDEK SCIENTIFIC LTD.
    Inventors: David ARKADIR, Yaron ILAN, Ari ZIMRAN
  • COMPOSITIONS AND METHODS FOR INDUCING THROMBOPOIESIS
    Publication number: 20190247464
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
  • TREATMENT FOR GLIOBLASTOMA
    Publication number: 20190240199
    Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
    Type: Application
    Filed: July 20, 2017
    Publication date: August 8, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Iris LAVON BEN MOSHE, Tamar CANELLO AVRAMOVITCH
  • SYSTEMS AND METHODS OF AUTOMATED IN-SITU PREPARATION FOR MOUNTING OF PREFABRICATED CUSTOM DENTAL PROSTHESIS
    Publication number: 20190209274
    Abstract: A system and method of automated formation of a preparation stub, based on an a priori created computational geometrical model, configured to conform to a prefabricated fixed dental prosthesis, is described. The system includes a digital imaging facility with an image acquiring device and a three-dimensional data digitizer, a modeling facility with an exterior surface design module and an interior surface design module, a fabrication facility operatively with a computer-aided manufacturing module, as well as an application facility including an ablation tool and in-situ preparation module; application facility preferably includes an intra-oral feedbacking appliance with a distance measurement probe for automated feedback-controlled formation of a preparation stub.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 11, 2019
    Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD, ROBOTOO INNOVATION LTD
    Inventors: Uri BARAK, Eyal TARAZI
  • Cell compositions and methods for cancer therapy
    Patent number: 10344073
    Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 9, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
  • Method of obtaining terminally differentiated neuronal lineages and uses thereof
    Patent number: 10336985
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: July 2, 2019
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios Karussis, Ibrahim Kassis
  • Alginate biomaterials for the treatment of hepatic disorders
    Patent number: 10328098
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Grant
    Filed: July 10, 2016
    Date of Patent: June 25, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Ya'acov, Smadar Cohen, Tsiona Elkayam
  • Method of treatment of diseases using hoodia extracts
    Patent number: 10314873
    Abstract: A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus Hoodia, wherein the disease is selected from the group consisting of immune-mediated disorders, immune-associated disorders, inflammatory diseases, coronary disease, insulin resistance and liver-related diseases. In a preferred embodiment, the Hoodia is Hoodia parviflora. Also disclosed is a pharmaceutical composition for treating the above diseases comprising an effective dosage of an extract of a plant of the genus Hoodia.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 11, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, DESERT LABS AGRICULTURE COOPERATIVE ASSOCIATION LTD.
    Inventors: Refael Aharon, Yaron Ilan
  • METHODS AND SYSTEM FOR ASSESSING A COGNITIVE FUNCTION
    Publication number: 20190167179
    Abstract: A method of neuropsychological analysis comprises: presenting to a subject, by a user interface, a subject-specific cognitive task having at least one task portion selected from the group consisting of a time-domain task portion, a space-domain task portion, and a person-domain task portion. The method also comprises receiving responses entered by the subject using the user interface for each of the task portions, representing the responses as a set of parameters, and classifying the subject into one of a plurality of cognitive function classification groups, based on the set of parameters.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 6, 2019
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Shahar ARZY
  • Compositions and methods for inducing thrombopoiesis
    Patent number: 10307462
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: June 4, 2019
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
  • HIGH THROUGHPUT SCREENING OF AGENTS ON DOPAMINERGIC NEURONS
    Publication number: 20190137482
    Abstract: A method of determining whether an agent is a neuroeffector is disclosed. The method comprises: (a) labeling dopaminergic neurons which are comprised in a mixed population of cells with a fluorescent dopamine analog; (b) measuring a level of fluorescence in the mixed population of cells; (c) exposing the mixed population of cells to the agent; (d) remeasuring a level of fluorescence in the mixed population of cells, wherein a change in the level of fluorescence is indicative of the substance being a neuroeffector.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 9, 2019
    Applicants: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Talya MORDECHAI DANIEL, Ofer WISER, Benjamin Eithan REUBINOFF
  • HYPERIMMUNE COLOSTRUM IN THE MODULATION AND TREATMENT OF CONDITIONS ASSOCIATED WITH THE MAMMALIAN MICROBIOME
    Publication number: 20190134096
    Abstract: Provided are methods and compositions which are applicable for modulating, preventing or treating non-clinical and clinical conditions that are associated with composition of mammalian microbiome. The methods and compositions are based on preparations of hyperimmune colostrum enriched with antibodies for lipopolysaccharides (anti-LPS), which directly or indirectly impact on the composition of mammalian microbiome and are applicable to alleviation and treatment of various forms of renal failure, hypertension, heart disease, atherosclerosis and sepsis, and various psychiatric and neurobehavioral conditions.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventor: Yaron ILAN
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 10266897
    Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: April 23, 2019
    Assignee: Hadasit Medical Research and Development Ltd.
    Inventor: Rifaat Safadi
  • POMEGRANATE OIL FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20190070111
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Application
    Filed: November 8, 2018
    Publication date: March 7, 2019
    Applicants: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth GABIZON, Haim OVADIA, Oded ABRAMSKY, Shlomo MAGDASSI, Liraz LARUSH
  • MICRO AND NANOPARTICULATE COMPOSITIONS COMPRISING ANTI-MICROBIALLY ACTIVE GROUPS
    Publication number: 20190053487
    Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.
    Type: Application
    Filed: February 26, 2017
    Publication date: February 21, 2019
    Applicants: NOBIO LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Nathan ZALTSMAN, Ervin I. WEISS
  • Targeting of innate immune response to tumor site
    Patent number: 10188741
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 29, 2019
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Plasminogen activator mutants as anti-fibrinolytic agents
    Patent number: 10188706
    Abstract: The invention relates to an anti fibrinolytic composition comprising at least one tPA mutant that carries at least one point mutation substituting Ser481 to Ala on tPA, said mutant inhibits the fibrinolytic activity of at least one of tPA and uPA and therefore may be used for treating disorders associated with fibrinolytic processes, specifically, coagulopathies, thrombocytopenia and bleeding. The invention further provides methods and uses of the mutants of the invention.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 29, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Abd Higazi, Nuha Hijazi
  • USE OF GUAIACOL FOR THE PREVENTION AND TREATMENT OF GLYCOGEN STORAGE DISEASE
    Publication number: 20190015355
    Abstract: The current invention is a method of preventing and treating certain diseases by preventing the synthesis and/or breakdown of glycogen by the administration of an agent, guaiacol. Diseases that can be prevented and treated by the administration of guaiacol include but are not limited to glycogen storage disease type IV (GSD-IV), adult polyglucosan body disease (APBD), and Lafora disease (LD). The invention also includes methods and tools for screening for agents that prevent and treat these diseases as well as basic research, specifically in the form of cells and cell lines that produce detectable polyglucosan.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Applicants: The Trustees of Couumbia University in the City of New York, Hadasit Medical Research Services and Development Ltd.
    Inventors: Hasan Orhan AKMAN, Salvatore DIMAURO, Or KAKHLON
  • Methods of obtaining cell populations enriched with desired cells
    Patent number: 10174285
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 8, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Sharona Cohen Evenram, Benjamin Reubinoff